In-hospital mortality higher for Asian patients, despite lower risk for hospital admission
COVID-19 Antibody Treatment Study Paused
ACTIV-3 study, testing use of an antibody therapy with remdesivir, paused ‘out of an abundance of caution’
Immune Responses Long-Lasting After Serious COVID-19
IgG levels remain elevated for four months in patients with symptoms lasting for 14 days
Individuals With Blood Group O Have Lower Risk for COVID-19
And more COVID-19 patients with blood group A or AB require mechanical ventilation, CRRT
COVID-19-Free Surgical Pathways May Aid Cancer Surgery Outcomes
Pulmonary complication, postoperative SARS-CoV-2 infection rates lower with COVID-19-free pathways
Second COVID-19 Vaccine Trial Paused for Unexplained Illness
Johnson & Johnson stopped its COVID-19 vaccine trial, which began phase 3 testing last month
Symptoms of COVID-19 Poor Marker for SARS-CoV-2 Infection
Only 13.9 percent of individuals with positive test reported specific symptoms on the day of the test
Bedside Tracheotomy Feasible for Critically Ill COVID-19 Patients
No infection identified among surgeons following procedure; postoperative complications rarely seen
CDC: U.S. COVID-19 Deaths Could Reach 233,000 by End of October
And, dual coronavirus-flu vaccine to start human trials
Remdesivir Cuts Time to COVID-19 Recovery
However, no significant difference in mortality found between remdesivir and placebo groups